Simulations Plus Inc
NASDAQ:SLP

Watchlist Manager
Simulations Plus Inc Logo
Simulations Plus Inc
NASDAQ:SLP
Watchlist
Price: 28.34 USD 0.04%
Market Cap: 568.8m USD
Have any thoughts about
Simulations Plus Inc?
Write Note

Simulations Plus Inc
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Simulations Plus Inc
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Simulations Plus Inc
NASDAQ:SLP
Other Long-Term Assets
$542k
CAGR 3-Years
76%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Veeva Systems Inc
NYSE:VEEV
Other Long-Term Assets
$401.3m
CAGR 3-Years
84%
CAGR 5-Years
52%
CAGR 10-Years
59%
Inspire Medical Systems Inc
NYSE:INSP
Other Long-Term Assets
$11m
CAGR 3-Years
280%
CAGR 5-Years
94%
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Other Long-Term Assets
$46.5m
CAGR 3-Years
112%
CAGR 5-Years
102%
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Other Long-Term Assets
$104.8m
CAGR 3-Years
9%
CAGR 5-Years
6%
CAGR 10-Years
16%
W
Waystar Holding Corp
NASDAQ:WAY
Other Long-Term Assets
$72.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Simulations Plus Inc
Glance View

Market Cap
568.2m USD
Industry
Health Care

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The company is headquartered in Lancaster, California and currently employs 135 full-time employees. The company provides prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology. The company also provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions in support of product approval. The company offers 11 software products for pharmaceutical research and development, which includes GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ADMET Predictor, MedChem Designer, MedChem Studio, PKPlus, KIWI and Monolix Suite of products through Lixoft. Its software and consulting services are provided to pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies and to academic and regulatory agencies worldwide for use in the conduct of industry-based research. Cognigen Corporation, DILIsym Services, Inc. and Lixoft are its subsidiaries.

SLP Intrinsic Value
19.62 USD
Overvaluation 31%
Intrinsic Value
Price

See Also

What is Simulations Plus Inc's Other Long-Term Assets?
Other Long-Term Assets
542k USD

Based on the financial report for Aug 31, 2024, Simulations Plus Inc's Other Long-Term Assets amounts to 542k USD.

What is Simulations Plus Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 3Y
76%

Over the last year, the Other Long-Term Assets growth was -71%. The average annual Other Long-Term Assets growth rates for Simulations Plus Inc have been 76% over the past three years .

Back to Top